ClinicalTrials.Veeva

Menu

A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)

Pharmacyclics logo

Pharmacyclics

Status and phase

Terminated
Phase 2

Conditions

Leukemia
Leukemia, Lymphocytic, Chronic

Treatments

Drug: Motexafin gadolinium

Study type

Interventional

Funder types

Industry

Identifiers

NCT00076401
PCYC-0216

Details and patient eligibility

About

The purpose of this study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have chronic lymphocytic leukemia (CLL) that has come back after treatment or that has stopped responding to treatment.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • At least 18 years old
  • Refractory or relapsed CLL
  • ECOG performance status score of 0, 1, or 2
  • Each patient must sign a study-specific informed consent form

Exclusion criteria

Laboratory values of:

  • Platelet count <30,000/uL
  • AST or ALT >2 x the upper limit of normal (ULN)
  • Total bilirubin >2 x ULN
  • Creatinine >2.0 mg/dL
  • Chemotherapy, radiation therapy, immunotherapy, systemic corticosteroids, or systemic biologic anticancer therapy within 21 days before beginning study treatment
  • Women who are pregnant or lactating

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems